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Abstract
High serum follicle-stimulating hormone (FSH) levels have been associated with diminished ovarian reserve; however, the
association between high urinary FSH and reduced natural fertility has yet to be established. We sought to characterize the rela-
tionship between a single or multiple measurements of early follicular phase urinary FSH and fertility. Women (n¼ 209), 30 to 44
years old with no history of infertility, who had been trying to conceive for less than 3 months, provided early follicular phase
urine. Participants subsequently kept a diary to record bleeding and intercourse and conducted standardized pregnancy testing
for up to 6 months. A subset of women (N¼ 95) collected urine on cycle day 3 for up to 6 cycles. Urine was analyzed for FSH and
creatinine (cr) corrected. Proportional hazard models were used to calculate fecundability ratios (FRs). Urinary FSH levels across
cycles from the same woman were highly correlated (adjusted intraclass correlation ¼ .77); within-woman variance was 3-fold
lower than variance among women. Women with an initial urinary FSH level <7 mIU/mg cr exhibited a nonsignificant reduction
in the probability of pregnancy (adjusted FR 0.71, 95% confidence interval [CI]: 0.45-1.13), as did women with elevated urinary
FSH (12 mIU/mg cr; adjusted FR 0.78, 95% CI: 0.46-1.32). Using the most recent or maximum urinary FSH value did not
strengthen the association. In the general population, urinary FSH levels appear to be nonlinearly associated with fertility; how-
ever, broad CIs indicate a lack of statistical significance. Repetitive testing appears to be of little benefit.
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Introduction
Women are delaying their attempts to conceive to later ages,
increasing the prevalence of age-related infertility.1 The Amer-
ican Society for Reproductive Medicine launched a campaign
in 2002 to increase awareness of age-related infertility. While
chronologic age is a strong predictor of fertility, women of sim-
ilar ages differ in their reproductive potential. Fertility tests
could potentially identify those women at risk for infertility due
to reproductive aging irrespective of their chronologic age.
Reproductive aging is thought to be due to the decline in the
quality and quantity (ovarian reserve) of oocytes and the folli-
cular pool.2–5 The decline in the follicular pool leads to less
production of inhibin, a granulosa cell product.6 Lower serum
inhibin levels lead to elevated early follicular phase serum
follicle-stimulating hormone (FSH) levels7 and a shortened fol-
licular phase.8 Accordingly, early follicular phase serum FSH
levels are inversely correlated with the number of follicles in
the ovary as determined histologically.9
Because urinary and serum FSH levels are strongly corre-
lated with each other,10,11 urinary FSH has been used as a tool
for field studies in epidemiology or for commercial testing in
at-home kits. A number of commercial urinary FSH kits are
FDA approved for this purpose and marketed to consumers.
However, the validity of these tests in predicting natural ferti-
lity has yet to be determined.
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In a preliminary analysis of 100 women, we noted a nonsigni-
ficant, 40% reduction in day-specific fecundability in women
with elevated urinary FSH values.12 We concluded that a larger
study was needed to refine estimates and to explore cutoff values.
In addition, the potential benefit of repetitive testing for predicting
fertility needs further study, as previous studies have shown sig-
nificant intercycle variability, especially among older women.13
Thus the objective of this study was to explore the potential value
of urinary FSH in predicting natural fertility, as measured by
cycle-specific and day-specific probabilities of conception.
Materials and Methods
Time to conceive, a time-to-pregnancy study, was approved
by the institutional review board of the University of North
Carolina. English-speaking women between 30 and 44 years
of age, who had been attempting to conceive for 3 months or
less or were about to start trying to conceive, were eligible for
participation in the study. Women with a history of infertility,
polycystic ovarian disease, pelvic inflammatory disease, endo-
metriosis, pelvic radiation, or with a partner with a history
of infertility were excluded from participation. Women were
recruited through community flyers, mass e-mails, and print
advertising. Eligible women were enrolled and provided
informed consent at their study visit, which was scheduled
for the second, third, or fourth menstrual cycle day (first day
defined as the first day of menses) following determination
of eligibility. Women, who were determined to be eligible
while contracepting, were enrolled in the menstrual cycle
immediately following cessation of birth control.
At the study visit, women provided a baseline urine sample.
A subset of this cohort agreed to collect first morning urine on
cycle days 2 and 3 in each subsequent cycle for up to 5 addi-
tional cycles or until pregnancy was detected. For each cycle,
urine samples were stored in the participant’s refrigerator for
up to 3 days and then shipped via overnight delivery in a cooler
with ice packs to the study center.
In the study center, all urine samples (5 mL) were trans-
ferred to polypropylene vials. To prevent degradation of FSH
that otherwise occurs in frozen samples, glycerol was added
to a final 7% dilution.14 The urine samples were stored frozen
at80C until analysis. While trying to conceive, women com-
pleted a study diary, which was designed to collect daily infor-
mation on vaginal bleeding, intercourse, pregnancy test results,
and medication use. Participants were asked to complete the
diary daily until pregnancy was detected or 3 menstrual cycles
had passed, whichever occurred first. Women were given free
home pregnancy tests (sensitivity ¼ 20 mIU hCG/mL) and
instructed to use them at the time of missed menses.
Women were instructed to inform study staff of a positive
pregnancy test and were provided a free pregnancy ultrasound
to encourage notification of pregnancy results. Women who did
not report a positive pregnancy test were contacted at 3 and 6
months after the study visit. Women were followed until a pos-
itive pregnancy test or until 6 months of attempt following the
study visit, whichever occurred first.
Urine samples were shipped frozen to the National Institute
for Occupational Safety and Health (NIOSH) Reproductive
Endocrinology Laboratory for endocrine analyses. Urinary FSH
concentrations were assayed in duplicate using a noncompeti-
tive, 2-site time-resolved immunofluorometric assay.15 Urinary
creatinine (cr) concentrations were measured using a Vitros
250 Chemistry Analyzer (Ortho-Clinical Diagnostics, Raritan,
New Jersey). Urinary FSH values were divided by the respective
sample’s creatinine concentration to adjust for urine flow rate.
All samples were measured in 1 assay per analyte. Intra-assay
coefficients of variation were 3.5% for FSH and 1.1% for cr.
When possible, the sample from cycle day 3 was selected for
analysis. If a sample from cycle day 3 was not available, a sam-
ple from cycle day 2 or day 4 was analyzed. We previously
showed high correlation between serum FSH and cr-corrected
urinary FSH within our cohort (r ¼ .85, P < .01).12
Statistical Analysis
Statistical analyses were performed with SAS version 9.2 (SAS
Institute, Cary, North Carolina), R 2.10.116, and WinBUGS
1.4.17 Initially, we evaluated the associations between the base-
line urinary FSH hormone levels and fecundability using the
full cohort (N ¼ 209) using discrete Cox proportional hazard
models to calculate a cycle-specific fecundability ratio
(FR).18 These models accounted for both the right censoring
and left truncation (due to women enrolling in the first, second,
third, or fourth cycle of pregnancy attempt) present in the data.
An FR less than 1.0 suggests reduced fecundability. Pregnancy
was defined by the report of a positive home pregnancy test.
Maternal age was classified into 3 categories for modeling
(30-34, 35-37, and 38-44 years of age). To determine the most
appropriate method to model cr-corrected urinary FSH,
Kaplan-Meier plots were used to examine time-to-pregnancy
by baseline FSH level (categorized <6.0, 6.0-6.9, 7.0-7.9,
8.0-8.9, 9.0-9.9, 10.0-10.9,11.0-11.9, 12.0-12.9, and 13.0
mIU/mg cr). Visual inspection of the 9 curves was used to cate-
gorize FSH into 3 groups (<7, 7-11.9 and12 mIU/mg cr). The
associated unadjusted FRs for the 9 categories illustrate the
nonlinear pattern (Figure 1).
Bivariate analyses were conducted to compare demographic
characteristics between women with low (<7 mIU/mg cr), mid-
dle (7-11.9 mIU/mg cr), and high (12 mIU/mg cr) urinary
FSH values. For categorical variables, unadjusted Cochran-
Mantel-Haenszel tests for association were used in order to take
advantage of the ordinal nature of some of these variables.19
For continuous variables, the nonparametric Kruskal-Wallis
test was employed.
To accommodate for differences in timing and frequency of
intercourse, the day-specific probabilities model by Scarpa and
Dunson20 was used to generate day-specific FRs. The model
accommodates multiple acts of intercourse during the fertile
window, assumes independence between acts of intercourse,
and allows for both the right censoring and left truncation pres-
ent in the data. Day-specific FRs were calculated using the sub-
cohort of women who provided urine and daily diary data
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(‘‘baseline urine and diary’’ subcohort, N ¼ 172). Information
from the diary on days of menstrual bleeding, days of inter-
course, and results of pregnancy tests were used to estimate
day-specific probabilities of pregnancy (probability of preg-
nancy given an act of intercourse on a fertile day). Ovulation
was assumed to have occurred 14 days prior to first day of
menses or first positive home pregnancy test, with the fertile
window designated as extending from 5 days before to 3 days
after day of ovulation based on the standard days method.21
Prospectively observed cycles were included in the model for
up to 3 observed cycles or until pregnancy was detected.
To determine the intercycle variability of urinary FSH, data
from the full cohort were subsequently analyzed, first using a
mixed model with the cycle-specific urinary FSH value, a ran-
dom intercept for each woman, and covariates (the pregnancy
attempt cycle, body mass index, age, and menstrual cycle day
of collection). Women with higher fecundability contributed
fewer cycles to the analysis of variance, which we define as
informative conception. To account for potential bias due to
informative conception, a mixed model and time-to-
conception model were jointly fit with a common random inter-
cept (Guo and Carlin model),22 also adjusting for pregnancy
attempt cycle, BMI, age, timing of void, and menstrual cycle
day of collection. The 2 models led to similar results, implying
that informative conception had little effect on estimates. Esti-
mates from the mixed model are presented.
To determine the value of repetitive urinary FSH testing in
the assessment of fecundability, the smaller ‘‘repetitive urine’’
subcohort (N ¼ 95), made up of those women who provided
multiple urine samples, was used to determine the associations
between (1) the baseline urinary FSH level, (2) the most recent
urinary FSH level, or (3) the maximum urinary FSH level and
fecundability using 3 separate, discrete Cox proportional
hazard models that allowed FSH to vary over time. Time-
varying FSH levels were included in the latter 2 models.
Results
Participant Characteristics
A total of 209 women provided a baseline urine sample and
completed follow-up; 95 of these women were enrolled in
the repetitive urine collection protocol with 71 women pro-
viding more than 1 urine sample. Of the 209 women, 172
women completed the study diary for at least 1 cycle while
trying to conceive. The full cohort and subcohorts did not
differ significantly by age distribution, parity, race, male part-
ner age, intercourse frequency, or distribution of baseline
FSH levels (Supplemental Table 1). However, time-to-
pregnancy was significantly longer in the repetitive urine
cohort (N ¼ 95) compared to those not in the repetitive urine
cohort (N ¼ 114; P ¼ .03). Time-to-pregnancy for the entire
cohort is shown in Supplemental Figure 1. Enrollment base-
line urinary FSH levels ranged from 2.37 to 41.42 mIU/mg
cr with a mean + standard deviation of 9.63 + 4.81 mIU/
mg cr (n ¼ 209).
Nonlinear Association Between Urinary FSH and
Fecundability
Given that elevated serum FSH is a marker for ovarian aging23
and is associated with decreased egg production in response to
ovarian stimulation,24 we anticipated that early follicular
phase urinary FSH would be inversely associated with
fecundability in our population. This was not the case. Both
low and high urinary FSH levels had lower point estimates
of fecundability (Figure 1).
The nonlinear association does not appear to be due to
chance selection that resulted in women with low FSH being
significantly different from the other participants. Character-
istics of the women varied little by urinary FSH level at
enrollment. Women with low (<7 mIU/mg cr), middle
(7-11.9 mIU/mg cr), and high (12 mIU/mg cr) FSH levels
are compared in Table 1. Across the levels of FSH, women did
not significantly differ in current use of tobacco, history of
sexually transmitted diseases, body mass index, cycle day of
urine collection, or self-reported menstrual cycle length. As
expected, women in the high FSH group were older (P ¼
.002). A larger proportion of women in the low and high
FSH group tended to have used hormonal birth control at
some point during the preceding year (P¼ .07). Women in the
low FSH group were most likely to report regular menstrual
cycles (P ¼ .04). Using data from the daily diaries, it was
noted that women in the lowest FSH group had the longest
observed menstrual cycles and greatest intercycle variance
in menstrual cycle length, although these findings were not
statistically significant.
Figure 1. Unadjusted fecundability ratios by level of baseline urinary
follicle-stimulating hormone ([FSH] mIU/mg cr). Women with values
from 7 to 7.9 mIU/mg cr served as the reference group.
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Association Between Baseline Urinary FSH and
Fecundability
Cycle-specific FRs for each category of baseline urinary FSH
were determined using the full cohort of women (N ¼ 209).
Women with urinary FSH values between 7 and 11.9 mIU/
mg cr served as the reference group. The association between
urinary FSH and fecundability appeared U shaped; women
with low urinary FSH levels and women with high urinary
FSH levels exhibited a nonsignificant 30% to 33% reduction
in fecundability (Table 2). Adjusting for age alone did not
significantly alter the association for women with low
urinary FSH but did slightly weaken the association for those
with high urinary FSH values. Further adjustment for hormo-
nal contraceptive use in the past year did not substantially
alter the association between low or high urinary FSH and
fecundability.
As estimated with the unadjusted day-specific probabilities
models, women (N¼ 172) with baseline urinary values of FSH
less than 7 mIU/mg cr exhibited a nonsignificant 42%
Table 2. Cycle-Specific and Day-Specific FRs With 95% CIs by Level of Baseline Urinary FSH Value in the Full Cohort.
Urinary FSH, mIU/mg cr
Cycle-Specific Fecundability Ratio Day-Specific Fecundability Ratio
FR 95% CI FR 95% CI
Unadjusted
<7 0.70 0.44-1.10 0.58 0.29-1.01
7-11 Reference Reference
12 0.67 0.41-1.12 0.58 0.25-1.08
Adjusted for age
<7 0.69 0.43-1.08 0.62 0.31-1.08
7-11 Reference Reference
12 0.75 0.45-1.27 0.63 0.27-1.18
Adjusted for age and hormonal contraceptive use
<7 0.71 0.45-1.13 0.68 0.31-1.25
7-11 Reference Reference
12 0.78 0.46-1.32 0.79 0.31-1.59
Abbreviation: CI, confidence interval; FR, fecundability ratios; FSH, follicle-stimulating hormone.
Table 1. Characteristics of Study Cohort by Baseline Level of Urinary FSH (Low, Middle, and High; N ¼ 209).a
Low (N ¼ 59),
<7 mIU/mg cr
Middle (N ¼ 108),
7-11.9 mIU/mg cr
High (N ¼ 42),
12 mIU/mg cr P Valueb
Age, years .002
30-34 45 (76) 78 (72) 21 (50)
35-37 9 (15) 19 (18) 9 (21)
38-44 5 (9) 11 (10) 12 (29)
Body mass index, kg/m2 .50
<18.5 2 (3) 3 (3) 1 (2)
18.5-24 37 (64) 70 (65) 24 (58)
25-29 11 (19) 24 (22) 8 (20)
30 8 (14) 11 (10) 8 (20)
History of gonorrhea or chlamydia 4 (7) 3 (3) 1 (2) .38
Current smoker 1 (2) 2 (2) 1 (2) .97
Hormonal contraceptivec use in past year 33 (57) 42 (39) 21 (50) .07
Menstrual cycle day of urine collection 3 (2-4) 3 (2-4) 3 (2-4) .80
Questionnaire: regular menstrual cycles 57 (97) 89 (83) 37 (88) .04
Diaryd: intercycle menstrual length variancee 7.0 (2.3-21.3) 4.5 (1.3-10.3) 4.3 (1.3-13.0) .24
Menstrual cycle length, days
Questionnaire 28.0 (28.0-30.0) 28.5 (28.0-30.0) 28.0 (27.0-29.5) .29
Diary datad 29.4 (27.0-32.6) 28.5 (27.0-31.4) 28.2 (26.3-31.5) .36
Abbreviations: cr, creatinine; FSH, follicle-stimulating hormone.
a Data presented as number (%) or median (interquartile range).
b For categorical variables, the Cochran-Mantel-Haenszel tests for association were used. For the continuous variables, the nonparametric Kruskal-Wallis test was
employed. P values were not adjusted for other variables in the table.
c Oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring.
d For women that have diary data (n ¼ 174).
e For women with diary data for more than 1 cycle (N ¼ 131).
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reduction in the probability of pregnancy, given an act of
intercourse on a fertile day compared to women with normal
urinary values. Women with elevated urinary FSH values
(12 mIU/mg cr) also exhibited a nonsignificant 42% reduc-
tion in probability of pregnancy (Table 2). After adjustment for
age and hormonal contraceptive use in the preceding year, the
associated reductions were weakened for women with low
urinary FSH and high urinary FSH.
Intercycle Variability of Urinary FSH
A woman’s urinary FSH values over multiple cycles were
highly correlated (adjusted intraclass correlation coefficient
¼ 0.77). Variance in urinary FSH between cycles within a
woman was significantly less than variance in urinary FSH
between women (variance components of 4.3 and 14.8, respec-
tively). Variability in FSH between cycles within a woman var-
ied by age of the woman (likelihood ratio test, P ¼ .001),
varying most in women 38 years of age (9.06) and least in
women <35 (3.3) as measured by mixed models. Guo and Car-
lin joint models, which account for informative dropout,
showed similar results. Of the 71 women who provided multi-
ple urine samples, 25 (35%) had no change in FSH categories
over time, 32 (45%) had changes between normal and low, 6
(9%) had changes between normal and high, and 8 (11%) had
a mixture of low, normal, and high FSH levels.
Repetitive Urinary Testing and Fecundability
The association between low and high urinary FSH and fecund-
ability was stronger in the smaller ‘‘repetitive urine’’ cohort (N
¼ 95) that provided early follicular phase urine samples in each
pregnancy attempt cycle for up to 6 cycles. These 95 women
contributed a total of 363 cycles to the analysis. Cycle-
specific FRs by level of FSH (baseline FSH, most recent FSH
value, or maximum FSH value) are presented in Table 3. Using
a woman’s maximum or most recent urinary FSH value
resulted in little substantive difference from analyses based
on the baseline urinary FSH value obtained during the first
study cycle. Adjusting for frequency and timing of intercourse
using day-specific fecundability analyses (N ¼ 71) revealed
similar results (data not presented).
Discussion
Findings from this study suggest that the relationship between
urinary FSH and fecundability may be hyperbolic, not linear,
with women with low or high FSH values both exhibiting
reduced fecundability. The findings were strongest in the ‘‘repe-
titive urine’’ group, but this may be due to chance associated
with the small sample size or composition of this group. While
statistically significant in the ‘‘repetitive urine’’ subcohort,
neither high nor low urinary FSH values were significantly asso-
ciated with fecundability in the full cohort. Most studies of the
relationship between FSH levels (urinary or serum) have not
described reduced fecundability in women with low FSH25,26;
however, these studies are generally conducted in women
receiving gonadotropin therapy for assisted reproduction. It is
possible that negative effects of low early follicular phase FSH
can be corrected with gonadotropin therapy.
There are a few studies of early follicular phase FSH levels
in women trying to conceive without gonadotropin therapy.
The largest study examined the relationship between early fol-
licular phase serum FSH levels and the probability of a sponta-
neous pregnancy within 12 months of infertility workup among
3519 couples with unexplained infertility.27 The authors found
a lower probability of pregnancy among women with serum
FSH values over 8 mIU/mL. The relationship between low
serum FSH and fecundability was not discussed; however, gra-
phically the data suggested a small, nonsignficant decline in
fecundability at lower FSH values. Li et al noted higher serum
and urinary peak FSH levels in conception cycles compared to
nonconception cycles among 14 women who conceived with
donor insemination.28 However, others have not noted a
Table 3. Cycle-Specific FRs With 95% CIs by Level of Baseline Urinary FSH Value, Most Recent Urinary FSH Value, and Maximum Urinary FSH
Value Among Women in the ‘‘Repetitive Urine’’ Subcohort.
Urinary FSH, mIU/mg cr
Fecundability Ratio, Unadjusted Fecundability Ratio, Adjusteda
Baseline FSH FR 95% CI FR 95% CI
<7 0.43 0.21-0.89 0.47 0.23-0.96
7-11 Reference
12 0.42 0.17-1.00 0.47 0.18-1.20
Most recent FSH
<7 0.44 0.22-0.84 0.41 0.21-0.81
7-11 Reference
12 0.60 0.24-1.49 0.75 0.28-2.01
Maximum FSH
<7 0.32 0.14-0.72 0.32 0.14-0.74
7-11 Reference
12 0.44 0.19-1.01 0.54 0.22-1.33
Abbreviations: CI, confidence interval; FR, fecundability ratios; FSH, follicle-stimulating hormone.
a Adjusted for age and hormonal contraceptive use in the previous year.
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relationship between FSH levels and conception following
intrauterine insemination without ovarian stimulation.29
It is possible that the women in our study with low urinary
FSH values (<7 mIU/mg cr, equivalent to <4.5 mIU/mL in
serum) exhibited hypothalamic–pituitary–ovarian (HPO) axis
dysfunction. Data from the North Carolina Early Pregnancy
Study suggest that low follicular phase luteinizing hormone
levels are also associated with reduced fecundability among
ovulatory women.30 The HPO dysfunction may lead to men-
strual cycle irregularities. Although participants with low urin-
ary FSH values were less likely to report menstrual cycle
irregularity than others, their menstrual cycle lengths as calcu-
lated from their daily diaries tended to be longer and exhibit
greater variability between cycles. A long menstrual cycle
length and menstrual cycle irregularity have been associated
with reduced fecundability.31,32
Low FSH levels could result in anovulatory cycles or ovula-
tory dysfunction with lower oocyte quality. In a randomized
controlled trial, a large dose of recombinant FSH at the time
of human chorionic gonadotropin trigger (mimicking the LH
surge) was associated with improved oocyte recovery rates and
fertilization following in vitro fertilization.33 Also, low FSH
levels could be indicative of luteal phase deficiency. Regularly
menstruating, exercising women with luteal phase defects have
been shown to have lower urinary FSH levels during the luteal–
follicular transition.34
Alternatively, women with lower early follicular phase urin-
ary FSH levels may have advanced follicular development
resulting in elevated estradiol levels and correspondingly sup-
pressed FSH. Advanced follicular development has been attrib-
uted to lower inhibin levels due to reproductive aging. Recent
hormone use could also suppress FSH levels and recent birth
control pill use has been associated with reduced fecundabil-
ity35; however, we adjusted for recent hormonal contraceptive
use and the relationship between low urinary FSH and reduced
fecundability persisted.
A general trend of reduced fecundability was observed
among women with elevated urinary FSH levels. High FSH
levels have been associated with diminished ovarian reserve
in clinical studies. However, the association between high urin-
ary FSH and reduced fecundability has yet to be established. A
number of home urinary FSH kits are marketed to consumers as
a fertility test. A positive test, and presumed reduced fertility, is
observed with elevated urinary FSH levels. A positive test is
noted when urinary values exceed the cutoff value equivalent
to a serum value of 10 mIU/mL. Using our assay, the equiva-
lent cutoff value would be 11.5 mIU/mg. Thus, all the women
in our high urinary FSH group would have tested positive.
While our point estimates would suggest that women with a
positive test (high FSH) would exhibit reduced fertility (1) the
confidence intervals (CIs) were wide and crossed one and (2) a
woman with a negative test cannot be reassured about her fer-
tility, diminishing its value as a ‘‘fertility test.’’ Given our study
sample, our findings should not be generalized to women
younger than age 30. Fertility tests would likely have poor pre-
dictive value in a group at low risk for reproductive aging.
As seen in previous studies, within a woman intercycle
variability of FSH is low.36 Previous studies have suggested
that variability of FSH levels increases with age.13 However,
younger women conceive in fewer cycles than older women,
which could lead to bias due to informative conception (women
with higher fecundability contribute fewer cycles to the analy-
sis of variance). Our analysis, which accounted for informative
conception, confirmed that variability of FSH increases with
age.
Information from repetitive testing of early follicular phase
urine for FSH does not appear to strengthen the association
between urinary FSH and fecundability; FRs using the time-
varying FSH models with the most recent urinary FSH value
were not significantly different from those models using only
the baseline FSH value. Sampling FSH values over multiple
cycles and choosing the maximum FSH also did not strengthen
the association. There appears to be little benefit to obtaining
urinary FSH values over multiple cycles to predict
fecundability.
In this study all baseline urine samples were non–first morn-
ing void urine samples, while 90% of the urine samples from
subsequent cycles were first morning void urines. This could
be viewed as a limitation in our study of the value of repetitive
urinary FSH testing. Most protocols measure urinary FSH in
first morning urine. However, we did adjust for cr in the sam-
ples, which should adjust for differing rates of urine production
(and subsequent concentrations) between samples. In general,
cr levels tend to be higher in first morning samples due to
decreased urine production overnight. However, early follicu-
lar phase serum FSH levels appear to have some diurnal var-
iation, with lower levels observed during sleep.37 Thus within
a woman, one can presume that a first void urine sample
would have lower cr-corrected FSH levels compared to a
urine sample collected later in the day. To accommodate for
differences in timing of collection in the urine samples, time
of urine collection (first morning void versus later) was added
to the model created to measure intercycle variability in urin-
ary FSH. This did not alter our conclusions that multiple mea-
sures are of little benefit.
After adjusting for factors (such as age, contraceptive use,
etc) which are correlated with urinary FSH levels, the CIs for
the adjusted FRs from the full cohort crossed one, so that the
observed effects of FSH may be driven by its relationship with
these factors, particularly age. If this were to be true, our con-
cerns about the validity of commercial urinary FSH kits would
remain. Women with partners who had known fertility prob-
lems were excluded from the study, but no semen analyses
were performed. We assumed that the prevalence of male sub-
fertility will be equally distributed across urinary FSH levels.
This study used models to measure the association between
urinary FSH and natural fertility: Cox models and day-
specific models, which adjust for frequency and timing of inter-
course. Results from the 2 models were similar.
In summary, early follicular phase urinary FSH values
appear to have a nonlinear association with fecundability in
women between the ages of 30 and 44; both low and high
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values suggest reduced fecundability. However, the findings of
reduced fecundability in both groups were not statistically sig-
nificant, suggesting the need for larger studies. Due to the gen-
erally low intercycle variability in urinary FSH, repetitive
urinary testing appears to be of little benefit. Future studies are
needed to confirm and further explore the potential mechanism
by which low early follicular phase FSH could lead to reduced
fertility. In the meantime, a woman with a negative fertility test
based on urinary FSH should not presume normal fertility.
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